These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17076695)

  • 1. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.
    Mant TG; Bradford D; Amin DM; Pisupati J; Kambayashi Y; Yano Y; Tanaka K; Yamada-Sawada T
    Br J Clin Pharmacol; 2007 May; 63(5):512-26. PubMed ID: 17076695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
    van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
    Wade A; Pawsey S; Whale H; Boyce M; Warrington S
    Clin Drug Investig; 2009; 29(5):325-37. PubMed ID: 19366274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.
    Lomeli BK; Galbraith H; Schettler J; Saviolakis GA; El-Amin W; Osborn B; Ravel J; Hazleton K; Lozupone CA; Evans RJ; Bell SJ; Ochsner UA; Jarvis TC; Baqar S; Janjic N
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
    Millar AW; Brown PD; Moore J; Galloway WA; Cornish AG; Lenehan TJ; Lynch KP
    Br J Clin Pharmacol; 1998 Jan; 45(1):21-6. PubMed ID: 9489589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
    Okour M; Gress A; Zhu X; Rieman D; Lickliter JD; Brigandi RA
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1088-1099. PubMed ID: 30950565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
    Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
    J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
    Min S; Song I; Borland J; Chen S; Lou Y; Fujiwara T; Piscitelli SC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):254-8. PubMed ID: 19884365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.
    Ino H; Wilson R; Terao T; Ogura H; Igarashi H; Cahn A; Numachi Y
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):78-86. PubMed ID: 30303626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
    Morain P; Robin JL; De Nanteuil G; Jochemsen R; Heidet V; Guez D
    Br J Clin Pharmacol; 2000 Oct; 50(4):350-9. PubMed ID: 11012558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
    Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ
    Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.